查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712496

全球骨壞死治療市場 - 2025-2033

Global Osteonecrosis Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年全球骨壞死治療市場規模達2.5322億美元，預計到2033年將達到4.0301億美元，在2025-2033年的預測期內複合年成長率為5.9%。

骨壞死，也稱為缺血性壞死、無菌性壞死或缺血性骨壞死，是一種因骨軟骨下區域血流中斷而導致骨細胞死亡的退化性骨病變。這種疾病最常影響承重關節處長骨的骨骺，在嚴重的情況下，會破壞軟骨下骨或導致整個關節塌陷。

股骨頭、膝關節、距骨和肱骨頭是骨壞死最常見的部位，而髖關節是最常受影響的關節。不太常見的是，它可以發生在其他骨骼中，例如腕骨或下顎骨。早期發現和介入對於有效治療骨壞死至關重要。這項活動探討了該疾病背後的原因和機制以及最常見受影響區域的表現和治療方案。

市場動態：

駕駛員和約束裝置

骨壞死發生率上升

骨壞死發生率的不斷上升是全球骨壞死治療市場擴張的重要驅動力。隨著越來越多的人被診斷出患有這種疾病，對有效治療方案的需求也隨之增加，推動了市場的成長。全球人口老化是導致骨壞死病例增加的主要因素。老年人罹患骨壞死的風險更高，尤其是髖關節。根據世界衛生組織（WHO）的數據，到2030年，每6人中就有1人年齡在60歲或以上，到2050年，60歲以上人口數將達到21億人。

骨壞死最常見於 60 歲及以上的人，其中髖關節最容易受到影響。創傷性損傷，尤其是道路交通事故造成的創傷，是導致骨壞死增加的主要原因，尤其是在年輕人身上。根據世界衛生組織（WHO）2023年12月的資料，每年約有119萬人死於道路交通事故。道路交通傷害是5至29歲兒童和年輕人死亡的主要原因。隨著外傷數量的增加，骨壞死病例的數量也會增加。這增加了對關節保護手術、截骨術和關節成形術等治療方案的需求。

骨壞死最常影響髖部，但也可發生在肱骨、膝蓋和距骨。這種症狀在腕部較小的骨頭（如月骨）中較不常見。雖然它也會影響下顎，但本綜述重點關注骨科醫生看到的更常見的形式。根據美國國家生物技術資訊中心 (NCBI) 2023 年 8 月的資料，在美國，10% 的全髖關節置換術是由於缺血性壞死 (AVN) 進行的，通常影響 30 至 65 歲的個人。

由於使用皮質類固醇、生活方式疾病、創傷和人口老化，骨壞死發生率不斷上升，對全球骨壞死治療市場產生了重大影響。這種日益加重的負擔推動了藥物和外科治療的創新，使骨壞死管理成為骨科和再生醫學行業中一個不斷成長的領域。

與治療相關的不良副作用

多種因素會增加雙磷酸鹽相關顎骨壞死（BRONJ）的風險，這可能會對全球骨壞死治療市場造成限制。根據美國國家生物技術資訊中心（NCBI）2023年7月的資料，拔牙、牙周治療、口腔植牙、使用假牙等牙科手術會加速骨轉換，增加骨壞死的風險。癌症、化療、低血紅蛋白、糖尿病、腎透析、高血壓、高脂血症和高膽固醇血症等疾病進一步增加了 BRONJ 的風險。

皮質類固醇、H2 阻斷劑、抗血管生成劑（例如舒尼替尼、貝伐單抗）、促紅血球生成素和環磷醯胺療法等藥物會影響骨骼代謝和免疫反應，從而增加 BRONJ 的風險。某些遺傳因素，例如法呢基焦磷酸合成酶或 CYP2C8 的多態性，可能使個體易患雙磷酸鹽相關的骨壞死，尤其是在多發性骨髓瘤患者中。年齡、飲酒和吸煙會進一步增加骨壞死的可能性，使治療選擇變得複雜。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按類型分類的程式碼片段
  • 治療片段
  • 依給藥途徑分類
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 骨壞死發生率上升
      • 醫療科技的進步
    • 限制
      • 與治療相關的不良副作用
      • 手術治療費用高昂
    • 機會
      • 對非侵入性治療的需求
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：骨壞死治療市場（按類型）

  • 創傷性
  • 非創傷性

第6章：骨壞死治療市場（依治療方法）

  • 非類固醇抗發炎藥
    • 布洛芬
    • 萘普生鈉
  • 血液稀釋劑
    • 華法林
    • 依諾肝素
  • 降膽固醇藥物
  • 骨質疏鬆症藥物
  • 雙磷酸鹽
    • 阿崙膦酸鈉
    • 利塞膦酸鹽
    • 唑來膦酸
    • 伊班膦酸鹽
  • 其他

第7章：骨壞死治療市場（依給藥途徑）

  • 口服
  • 腸外

第8章：骨壞死治療市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Pfizer Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Haleon Group of Companies
  • BASF Corporation
  • Johnson & Johnson
  • Bayer AG
  • Sanofi
  • Upsher-Smith Laboratories, LLC.
  • Merck & Co., Inc
  • Procter & Gamble Pharmaceuticals, Inc.
  • Novartis AG
  • Eugia US
  • Dr. Reddy's Laboratories
  • Amgen Inc.

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: PH7228

The global osteonecrosis treatment market reached US$ 253.22 million in 2024 and is expected to reach US$ 403.01 million by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.

Osteonecrosis, also referred to as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a degenerative bone condition caused by the interruption of blood flow to the bone's subchondral area, leading to the death of bone cells. This condition most commonly affects the epiphysis of long bones at weight-bearing joints and, in severe cases, can destroy the subchondral bone or cause the collapse of an entire joint.

The femoral head, knee, talus, and humeral head are the most frequent sites for osteonecrosis, with the hip being the most commonly affected joint. Less commonly, it can occur in other bones such as the carpus or jaw. Early detection and intervention are crucial for the effective management of osteonecrosis. This activity explores the causes and mechanisms behind the disease and the presentation and treatment options for the most commonly affected areas.

Market Dynamics: Drivers & Restraints

Rising Incidence of Osteonecrosis

The growing incidence of osteonecrosis is a significant driver for expanding the global osteonecrosis treatment market. As more individuals are diagnosed with this condition, the demand for effective treatment options increases, fueling market growth. The aging global population is a major factor contributing to the rising number of osteonecrosis cases. Older individuals are at a higher risk of developing osteonecrosis, particularly in the hip joint. According to the World Health Organization (WHO), by 2030, 1 in 6 people will be aged 60 or older, and by 2050, the number of people aged 60 and above will reach 2.1 billion.

Osteonecrosis is most common in individuals aged 60 and above, with the hip joint being the most frequently affected. Traumatic injuries, particularly from road accidents, are key contributors to the rise in osteonecrosis, especially in younger individuals. As per World Health Organization (WHO) data in December 2023, around 1.19 million people die annually due to road traffic accidents. Road traffic injuries are the leading cause of death among children and young adults aged 5 to 29 years. As the number of traumatic injuries increases, so will the number of osteonecrosis cases. This increases the demand for treatment options like joint preservation surgery, osteotomy, and arthroplasty.

Osteonecrosis most commonly affects the hip but can also occur in the humerus, knee, and talus. It is less frequently seen in the smaller bones of the wrist, like the lunate. While it can also impact the jaw, this review focuses on the more common forms seen by orthopedic surgeons. According to the National Center for Biotechnology Information (NCBI) data in August 2023, in the United States, 10% of total hip arthroplasties are performed due to avascular necrosis (AVN), typically affecting individuals aged 30 to 65.

The increasing incidence of osteonecrosis, driven by corticosteroid use, lifestyle diseases, trauma, and an aging population, is significantly impacting the global osteonecrosis treatment market. This rising burden is pushing forward innovations in both pharmacological and surgical treatments, making osteonecrosis management a growing segment within the orthopedic and regenerative medicine industries.

Adverse Side Effects Associated with Treatment

Several factors increase the risk of developing bisphosphonate-related osteonecrosis of the jaw (BRONJ), which can act as a restraint in the global osteonecrosis treatment market. According to the National Center for Biotechnology Information (NCBI) data in July 2023, dental surgeries such as tooth extractions, periodontal treatments, oral implants, and the use of dentures can heighten bone turnover and increase the risk of osteonecrosis. Conditions like cancer, chemotherapy, low hemoglobin, diabetes, renal dialysis, hypertension, hyperlipidemia, and hypercholesterolemia further elevate the risk of developing BRONJ.

Drugs such as corticosteroids, H2 blockers, antiangiogenic agents (e.g., sunitinib, bevacizumab), erythropoietin, and cyclophosphamide therapy can increase the risk of BRONJ by affecting bone metabolism and immune response. Certain genetic factors, such as polymorphisms in farnesyl pyrophosphate synthase or CYP2C8, may predispose individuals to bisphosphonate-associated osteonecrosis, particularly in patients with multiple myeloma. Age, alcohol consumption, and tobacco use can further increase the likelihood of developing osteonecrosis, complicating treatment options.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, route of administration, and region.

Treatment:

The non-steroidal anti-inflammatory drugs segment in treatment is expected to dominate the global osteonecrosis treatment market with the highest market share

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as a first-line treatment to manage pain and inflammation associated with osteonecrosis, a condition characterized by the death of bone tissue due to reduced blood supply. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for inflammation and pain. In osteonecrosis, NSAIDs are primarily prescribed to provide symptomatic relief and to manage associated conditions such as arthritis.

The increasing prevalence of osteonecrosis due to factors such as prolonged corticosteroid use, alcohol consumption, trauma, and autoimmune diseases is driving demand for NSAIDs.Due to concerns over opioid addiction, many healthcare providers prefer NSAIDs as a safer alternative for pain management.NSAIDs are available in oral, topical, and injectable forms, offering flexibility in administration for different patient needs. With an aging population prone to bone-related conditions like osteoporosis and osteonecrosis, NSAID demand is expected to grow. These factors have solidified the segment's position in the global osteonecrosis treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global osteonecrosis treatment market, with the highest market share

Osteonecrosis is a significant cause of hip arthroplasties in the U.S., affecting individuals primarily between the ages of 30 and 65. Around 10% of total hip replacements are due to avascular necrosis, indicating a strong demand for treatment solutions. The increasing number of elderly individuals in North America contributes to the demand for osteonecrosis treatments. In the U.S., 17% of the population was 65 or older in 2022, and this demographic is at a higher risk of developing osteonecrosis, further driving market growth.

The development of innovative treatment options, such as ozone injections for medication-related osteonecrosis of the jaw (MRONJ), is expected to boost the market. These treatments provide effective alternatives to surgical intervention for complex cases. The market has seen several approvals for osteonecrosis-related medications. For instance, in June 2022, Strides Pharma received FDA approval for its Ibuprofen suspension. The U.S. market for this product is estimated to be approximately $41 million, and it will be produced at the company's facility in Bengaluru. Thus, the above factors are consolidating the region's position as a dominant force in the global osteonecrosis treatment market.

Competitive Landscape

The major global players in the osteonecrosis treatment market include Pfizer Inc., Haleon Group of Companies, BASF Corporation, Johnson & Johnson, Bayer AG, Sanofi, Upsher-Smith Laboratories, LLC., Merck & Co., Inc., Procter & Gamble Pharmaceuticals, Inc., Novartis AG, Eugia US, Dr. Reddy's Laboratories, and Amgen Inc. among others.

Key Developments

  • In March 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global osteonecrosis treatment market report delivers a detailed analysis with 71 key tables, more than 56 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Treatment
  • 2.5. Snippet by Route of Administration
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Incidence of Osteonecrosis
      • 3.1.1.2. Advancements in Medical Technology
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Side Effects Associated with Treatment
      • 3.1.2.2. High Costs Associated with Surgical Treatments
    • 3.1.3. Opportunity
      • 3.1.3.1. Demand for Non-Invasive Treatments
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Regulatory and Reimbursement Landscape
    • 4.4.1. North America
    • 4.4.2. Europe
    • 4.4.3. Asia Pacific
    • 4.4.4. South America
    • 4.4.5. Middle East & Africa
  • 4.5. Porter's Five Forces Analysis
  • 4.6. Supply Chain Analysis
  • 4.7. Patent Analysis
  • 4.8. SWOT Analysis
  • 4.9. Unmet Needs and Gaps
  • 4.10. Recommended Strategies for Market Entry and Expansion
  • 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.12. Pricing Analysis and Price Dynamics
  • 4.13. Key Opinion Leaders

5. Osteonecrosis Treatment Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Traumatic*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Nontraumatic

6. Osteonecrosis Treatment Market, By Treatment

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 6.1.2. Market Attractiveness Index, By Treatment
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Ibuprofen
    • 6.2.4. Naproxen Sodium
  • 6.3. Blood Thinners
    • 6.3.1. Warfarin
    • 6.3.2. Enoxaparin
  • 6.4. Cholesterol-Lowering Drugs
  • 6.5. Osteoporosis Drugs
  • 6.6. Bisphosphonates
    • 6.6.1. Alendronate
    • 6.6.2. Risedronate
    • 6.6.3. Zoledronic Acid
    • 6.6.4. Ibandronate
  • 6.7. Others

7. Osteonecrosis Treatment Market, By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Parenteral

8. Osteonecrosis Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Haleon Group of Companies
  • 10.3. BASF Corporation
  • 10.4. Johnson & Johnson
  • 10.5. Bayer AG
  • 10.6. Sanofi
  • 10.7. Upsher-Smith Laboratories, LLC.
  • 10.8. Merck & Co., Inc
  • 10.9. Procter & Gamble Pharmaceuticals, Inc.
  • 10.10. Novartis AG
  • 10.11. Eugia US
  • 10.12. Dr. Reddy's Laboratories
  • 10.13. Amgen Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us